Mach7 Technologies (ASX:M7T) - Managing Director, Mike Lampron
Managing Director, Mike Lampron
Source: Mach7 Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical imaging software specialist Mach7 Technologies (M7T) has revealed a healthy balance sheet to kick off the new financial year after a cashflow-positive June quarter
  • After raising $22.9 million from investors and going cashflow-positive by around $3.5 million for the June quarter, Mach7 had just under $49 in the bank at the end of June
  • Of course, a big chunk of the cash will go towards the $40.9 million Client Outlook purchase, which Mach7 announced in June
  • Over the June quarter, Mach7 said it generated $9.2 million in new sales contracts over the June quarter
  • The company has hired an advisory firm to help integrate the Mach7 and Client Outlook tech
  • Shares in Mach7 closed 13.22 per cent higher today, worth 98 cents each

Medical imaging software company Mach7 Technologies (M7T) has revealed a healthy balance sheet to kick off the new financial year after a cashflow-positive June quarter.

The company had just under $49 million cash in the bank at the end of June after taking in $6.5 million from customer receipts. With just over $3 million in operating expenses, this means Mach7 went cashflow-positive by roughly $3.5 million for the quarter.

The company said for the full 2020 financial year, it was cashflow positive by $4.5 million. Moreover, the company said it generated $9.2 million of new sales contracts over the June quarter, taking total contact value for annual sales to $19.4 million for the 2020 financial year.

Of course, Mach7’s cash balance was supported by a share placement and entitlement offer which pulled in $22.9 million.

The funds were raised to buy out Canadian company Client Outlook for $40.9 million. Mach7 wanted to get its hands on Client Outlook for the Canadian company’s eUnity enterprise image viewing tech platform.

Essentially, eUnity gives clinicians quick and easy access to high-quality medical images from anywhere in the world and on any device. The clinicians can see the same high-quality images as a radiologist through the eUnity interface, which can be installed on computers, tablets, and mobile phones.

On the other hand, Mach7’s tech is made to streamline the medical imaging process by optimising storage, workflow, patient management, and more throughout a hospital’s full IT ecosystem. As such, the eUnity and Mach7 tech are highly complementary.

Of course, the $40.9 million has not yet been paid; Mach7 plans to make the payment on or before September 30, 2020. Thus, the strong balance sheet will be drained before the end of the quarter, but not without its rewards. Mach7 has already hired an advisory firm to help integrate Client Outlook’s tech with its own tech platform.

Investors seemed impressed with today’s quarterly update, with Mach7 shares closing 13.22 per cent higher at 98 cents each. The company has a $230 million market cap.

M7T by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…